Actively Recruiting
Evaluation of Line-field Confocal Optical Coherence Tomography for Diagnosing Basal Cell Carcinoma in Routine Clinical Practice A Retrospective Observational Study
Led by Maastricht University Medical Center · Updated on 2026-10-19
297
Participants Needed
1
Research Sites
15 weeks
Total Duration
AI-Summary
What This Trial Is About
Basal cell carcinoma BCC is the most common skin cancer in the Netherlands, and its incidence continues to rise. The standard diagnosis combines clinical evaluation and dermoscopy, while biopsy and histopathological examination remain the gold standard when diagnosis is uncertain. This study evaluates line-field confocal optical coherence tomography LC-OCT, a non-invasive imaging technique, as a promising alternative to biopsy for suspected BCC lesions in routine clinical practice. LC-OCT combines conventional optical coherence tomography and reflectance confocal microscopy to create three-dimensional, cellular-level images of the skin. This retrospective observational study includes patients with clinically suspected BCC lesions who underwent LC-OCT imaging as part of routine care at dermatology clinics. The study focuses on real-world clinical performance and utility of LC-OCT in the diagnosis and management of BCC. Participants tumor-free survival will be measured from enrollment to 6-12 months after treatment. Researchers will also evaluate diagnostic accuracy for BCC detection, treatment strategies, the number of LC-OCT scans performed, lesion characteristics at baseline, and the proportion of biopsies that were avoided. Data include histopathological results or clinical follow-up over 6 to 12 months. The study period runs from June 2026 to December 2027.
CONDITIONS
Brief Title
Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice
Research Team
Y
Yara Valkenburg, MD
K
Klara Mosterd, MD PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here